



EMLc

ATC codes: **N02BA01**

Indication	Mucocutaneous lymph node syndrome <span style="background-color: #00a651; color: white; padding: 2px;">ICD11 code: 4A44.5</span>
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Additional notes	Acute or chronic use for rheumatic fever, juvenile arthritis , Kawasaki disease
Formulations	Oral > Solid: 100 to 500 mg Local > Rectal > Suppository: 50 to 150 mg
EML status history	First added in 2007 (TRS 950) Changed in 2013 (TRS 985)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .
Wikipedia	<a href="#">Acetylsalicylic acid</a>
DrugBank	<a href="#">Acetylsalicylic acid</a>

## Summary of evidence and Expert Committee recommendations

A new section of the Model Lists for “Medicines for diseases of joints” was created to list the treatments for gout and the disease-modifying agents used in rheumatoid disorders and juvenile joint diseases that were previously included in Section 2. Thus, acetylsalicylic acid for the treatment of Kawasaki disease in children was transferred to this new section.

